CG Oncology’s Post

Encouraging #results of the #BOND-003 trial evaluating #cretostimogene grenadenorepvec, CG Oncology's novel oncolytic immunotherapy candidate, in high-risk Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive #Bladder Cancer (#NMIBC).

For patients with advanced or recurrent #EndometrialCancer, first-line Lenvima plus Keytruda didn’t significantly improve outcomes versus chemotherapy. Journal of Clinical Oncology #Oncology https://lnkd.in/e7PCudhV

Results from the IMpassion132 trial presented at #ESMOBreast24 reveal that adding atezolizumab to chemotherapy does not improve overall survival in patients with advanced triple-negative breast cancer (#TNBC) relapsing within 12 months after initial treatment. However, according to Carmen Criscitiello, the higher objective response rate achieved with atezolizumab suggests that at least some patients could benefit from it, and this highlights the importance of individualised treatment approaches. 👇Read more in the #ESMODailyReporter article https://ow.ly/GRIy50RH8VL

Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations. American Society of Clinical Oncology (ASCO) #oncology #NSCLC https://lnkd.in/eQ8h-M9A

Professor Park Yeon-hee: “No further data expected…Coverage for Keytruda in early triple-negative breast cancer needed” - [Interview] "Goal to cure triple-negative breast cancer... Keytruda has proven more beneficial for reimbursement despite economic feasibility evaluation" - "Korean female patients' age group is lower than other countries... No drugs approved for early reimbursement" - ESMO unveils 'KN-522' data: Keytruda combination reduces death risk by 34% compared to chemotherapy alone - 5-year overall survival (OS): Keytruda combination at 86.6% vs. placebo group at 81.7% https://lnkd.in/gUzuXNPf

Professor Park Yeon-hee: “No further data expected…Coverage for Keytruda in early triple-negative breast cancer needed” - [Interview] "Goal to cure triple-negative breast cancer... Keytruda has proven more beneficial for reimbursement despite economic feasibility evaluation" - "Korean female patients' age group is lower than other countries... No drugs approved for early reimbursement" - ESMO unveils 'KN-522' data: Keytruda combination reduces death risk by 34% compared to chemotherapy alone - 5-year overall survival (OS): Keytruda combination at 86.6% vs. placebo group at 81.7% https://lnkd.in/gvHtFbU2

🔍 New Insights on HER2 Levels in Triple-Negative Breast Cancer 📊 A recent study reveals that higher HER2 expression in triple-negative breast cancer (TNBC) patients significantly predicts poorer survival outcomes, even with adjuvant capecitabine treatment. 📅 Conducted from June 2017 to December 2023, this pivotal research analyzed 112 TNBC patients and found that those with HER2 2+ expression faced a median overall survival of just 27.5 months, compared to 84.5 months for those with lower levels (HER2 0/1+). Key findings include: - Overall survival rate at five years: 62.6% - Relapse-free survival rate: 55.8% - Direct correlation between elevated HER2 levels and reduced survival rates These results underscore the importance of integrating anti-HER2 therapies into treatment plans for TNBC patients exhibiting elevated HER2 levels, paving the way for personalized strategies that could enhance patient outcomes. 💡 Understanding the relationship between HER2 status and treatment efficacy is vital for optimizing care protocols. For a deeper dive into this critical research, click on the link! #BreastCancer #CancerResearch #General #HER2 #Oncology #PersonalizedMedicine #TNBC #MarketAccess #MarketAccessToday

🔍 Intensive Monitoring Essential for Breast Cancer Chemotherapy Success 🎗️ Recent research underscores the critical need for vigilant monitoring during neoadjuvant chemotherapy (NACTx) for breast cancer patients. A comprehensive six-year study reviewed 242 patient records, revealing that over 20% faced severe treatment-related adverse events, with 21.5% experiencing grade 3 complications. Key findings include: - 2.2% developed anthracycline-induced cardiotoxicity - 27% achieved pathological complete response (pCR) - Variability in treatment responses based on molecular subtypes The study emphasizes the importance of personalized treatment plans and a multidisciplinary approach to optimize outcomes and reduce severe adverse events. Healthcare providers are encouraged to implement tailored therapies and enhance monitoring protocols to navigate the complexities of breast cancer treatment effectively. 👉 Click on the link to learn more about these vital findings! #BreastCancer #Chemotherapy #ClinicalResearches #HealthcareInnovation #OncologyResearch #PatientCare #Publications #RegulatoryAgencies #MarketAccess #MarketAccessToday

Are your patients with HR+/HER2− early breast cancer at high risk for recurrence? Early identification of high-risk features is crucial for preventing disease relapse and improving long-term outcomes. In this Rapid Research Review, explore how CDK4/6 inhibitors, combined with endocrine therapy, can enhance treatment efficacy for these patients. You’ll gain insights from expert faculty, learn strategies for managing treatment-related adverse events, and discover how to integrate these evolving therapies into your clinical practice. Stay ahead of the latest advancements in adjuvant treatment for high-risk HR+/HER2− early breast cancer: https://ow.ly/4U4p50TLKzo #BreastCancer #Oncology #CDK46Inhibitors #CommunityCare #CancerResearch #CancerTreatment

Are your patients with HR+/HER2− early breast cancer at high risk for recurrence? Early identification of high-risk features is crucial for preventing disease relapse and improving long-term outcomes. In this Rapid Research Review, explore how CDK4/6 inhibitors, combined with endocrine therapy, can enhance treatment efficacy for these patients. You’ll gain insights from expert faculty, learn strategies for managing treatment-related adverse events, and discover how to integrate these evolving therapies into your clinical practice. Stay ahead of the latest advancements in adjuvant treatment for high-risk HR+/HER2− early breast cancer: https://ow.ly/k2lz50TYeMn #BreastCancer #Oncology #CDK46Inhibitors #CommunityCare #CancerResearch #CancerTreatment